Adding Cetuximab to Chemo Curbs Survival in Resectable Colorectal Liver Metastasis Adding Cetuximab to Chemo Curbs Survival in Resectable Colorectal Liver Metastasis
The combination of chemotherapy and the epidermal-growth-factor receptor (EGFR) antibody cetuximab shortens survival compared with chemotherapy alone in certain patients with colorectal cancer, according to an open-label randomized trial.Reuters Health Information
Source: Medscape Medical News Headlines - Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news
More News: Cancer | Cancer & Oncology | Chemotherapy | Colorectal Cancer | Erbitux | Health | Hematology | Liver | Urology & Nephrology